Sarclisa (isatuximab)

Brand Name: Sarclisa
Innovator Brand Name: Sarclisa
API: Isatuximab
Dosage Form: 1 Vial (Per Box)
Strength: 100 mg/5 mL & 500 mg/25 mL
Manufacturer Name: Sanofi


Sarclisa Isatuximab-irfc Injection

Sarclisa (isatuximab-irfc) is a CD38 directed cytolytic antibody used, in combination with pomalidomide and dexamethasone, to treat adult patients with multiple myeloma who have received at least a couple of prior therapies including lenalidomide and a proteasome inhibitor.

Dosage: The recommended dose of Isatuximab is 10 mg/kg actual body weight administered as an intravenous infusion in combination with medicine pomalidomide and dexamethasone. During Cycle-1, it is given on Days 1, 8, 15, and 22 (weekly), and during Cycle-2 and beyond it is given on Days 1, 15 (every 2 weeks). Each treatment cycle consists of a 28-day period. Treatment is repeated until the disease is progressive or unacceptable toxicity occurs. If a planned dose of Isatuximab is missed, administer the dose as soon as possible and adjust the treatment schedule accordingly, maintaining the treatment interval.

Side Effects: The most commonly reported sarclisa side effects (incidence ≥ 20%) include:

  • diarrhea
  • neutropenia
  • infusion-related reactions
  • pneumonia
  • upper respiratory tract infection

Warnings and Precautions:

  • In order to reduce the risk and severity of infusion-related reactions, premedicate patients prior to sarclisa 100 mg / 500 mg infusion with acetaminophen, H2 antagonists, diphenhydramine, or equivalent; dexamethasone.
  • Monitor patients with sarclisa 500 mg / 100 mg for complete blood cell counts periodically during therapy. Consider the use of antibiotics as well as antiviral prophylaxis while on therapy.
  • Permanently discontinue Isatuximab therapy if a grade 3 or higher infusion-related reaction occurs and institute apt medical management.
  • Monitor patients with sarclisa dosage for the development of second primary malignancies, as per International Myeloma Working Group (IMWG) guidelines.
  • Women of the potential hazard to a fetus should avoid becoming pregnant during treatment and for at least 5 months following the last dose of sarclisa multiple myeloma medication.
  • Respective nursing women receiving treatment with Isatuximab injection should avoid breastfeeding during the course of treatment.

More info

Storage: Store sarclisa vials in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton in order to protect from light. Do not freeze. Do not shake. Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the SARCLISA at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the SARCLISA Injections. Buying Procedure: In order to buy SARCLISA, you can contact us at our TOLL-FREE Number: 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: along with the legitimate ID Proof, Standard Prescription and Medical Reports. Conclusions: The addition of isatuximab medication to pomalidomide and dexamethasone led to more frequent durable complete renal responses and improved PFS and disease response rates across different subgroups of patients with relapsed/refractory multiple myeloma, independent of the increased-risk cytogenetic status, renal impairment, age of patients or number of prior lines of therapies or refractory status. The treatment with isatuximab, pomalidomide and dexamethasone was able to overcome the adverse risk factors of age, refractory status and number of prior lines, resulting in similar progression free survival in comparison to the overall ICARIA-MM population.


What is Sarclisa? Sarclisa (API: Isatuximab) is a monoclonal antibody (mAb) medicine approved for the treatment of MM (Multiple Myeloma). When was Sarclisa FDA approved? On March 31, 2021, Sarclisa was approved by the US Food and Drug Administration. What kind of drug is Sarclisa? Sarclisa is a targeted immunotherapy that works together with your defense (immune) system. What does Sarclisa contain as an active substance? The medication Sarclisa specifically contains the active substance Isatuximab. How much does sarclisa cost? The sarclisa price in India usually can vary depending on the wholesaler/pharmacy you visit. Sarclisa is available as a brand name drug only, a generic version is not yet available. What is the best price for Isatuximab? Please contact Toll-free: +91 1800 889 1064 |+919310090915 for isatuximab price in India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements. Can I get Sarclisa (Isatuximab) even if I am not based in India? The Indian Pharma helps patients in accessing or importing Sarclisa (Isatuximab), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.